Abstract:Human immunodeficiency virus type 1 (HIV-1) entry into the host cell involves a cascade of events and currently represents one of most attractive targets in the search for new antiviral drugs. The fusion-active gp41 core structure is a stable six-helix bundle (6-HB) folded by its trimeric N-terminal heptad repeat (NHR) and C-terminal heptad repeat (CHR). Peptides derived from the CHR region of HIV-1 gp41 are potent fusion inhibitors that target the NHR to block viral and cellular membrane fusion in a dominant negative fashion. However, all CHR peptides reported to date are derived primarily from residues 628 to 673 of gp41; little attention has been paid to the upstream sequence of the pocket binding domain (PBD) in the CHR. Here, we have identified a Motif ((621)QIWNNMT(627)) located at the upstream region of the gp41 CHR, immediately adjacent to the PBD ((WMEWEREI635)-W-628). Biophysical characterization demonstrated that this motif is critical for the stabilization of the gp41 6-HB core. The peptide CP621-652, containing the (621)QIWNNMT(627) motif, was able to interact with T21, a counterpart peptide derived from the NHR, to form a typical 6-HB structure with a high thermostability (thermal unfolding transition [T-m] value of 82 degrees C). In contrast, the 6-HB formed by the peptides N36 and C34, which has been considered to be a core structure of the fusion-active gp41, had a T-m of 64 degrees C. Different from T-20 (brand name Fuseon), which is the first and only HIV-1 fusion inhibitor approved for clinical use, CP621-652 could efficiently block 6-HB formation in a dose-dependent manner. Significantly, CP621-652 had potent inhibitory activity against HIV-1-mediated cell-cell fusion and infection, especially against T-20- and C34-resistant virus. Therefore, our works provide important information for understanding the core structure of the fusion-active gp41 and for designing novel anti-HIV peptides.

Hydrophobic Mutations In Buried Polar Residues Enhance Hiv-1 Gp41 N-Terminal Heptad Repeat-C-Terminal Heptad Repeat Interactions And C-Peptides' Anti-Hiv Activity

Mutations of Gln64 in the HIV-1 Gp41 N-Terminal Heptad Repeat Render Viruses Resistant to Peptide HIV Fusion Inhibitors Targeting the Gp41 Pocket

Conserved Residue Lys574 in the Cavity of HIV-1 Gp41 Coiled-coil Domain is Critical for Six-helix Bundle Stability and Virus Entry*

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Helical Interactions in the HIV-1 Gp41 Core Reveal Structural Basis for the Inhibitory Activity of Gp41 Peptides.

Identification Of A Critical Motif For The Human Immunodeficiency Virus Type 1 (Hiv-1) Gp41 Core Structure: Implications For Designing Novel Anti-Hiv Fusion Inhibitors

ST103 HIV-1 Variants with Mutations in the Gp41 Pocket Region Are Resistant to HIV Fusion Inhibitors with Pocket-Binding Domain, but Sensitive to T20

Adding An Artificial Tailanchor To A Peptide-Based Hiv-1 Fusion Inhibitor For Improvement Of Its Potency And Resistance Profile

HIV Gp41 C-terminal Heptad Repeat Contains Multifunctional Domains: RELATION TO MECHANISMS OF ACTION OF ANTI-HIV PEPTIDES

The Conserved Residue Arg46 in the N-Terminal Heptad Repeat Domain of HIV-1 Gp41 is Critical for Viral Fusion and Entry

HIV-1 Variants with a Single-Point Mutation in the Gp41 Pocket Region Exhibiting Different Susceptibility to HIV Fusion Inhibitors with Pocket- or Membrane-Binding Domain.

Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

Conserved Salt Bridge Between the N- and C-Terminal Heptad Repeat Regions of the Human Immunodeficiency Virus Type 1 Gp41 Core Structure is Critical for Virus Entry and Inhibition

Adding an Artificial Tail—Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile

Design, Synthesis and Activity Evaluation of Novel Peptide Fusion Inhibitors Targeting HIV-1 Gp41

A Salt Bridge Between An N-Terminal Coiled Coil Of Gp41 And An Antiviral Agent Targeted To The Gp41 Cove Is Important For Anti-Hiv-1 Activity

Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion.

Identification of Critical Antibody-Binding Sites in the HIV-1 Gp41 Six-Helix Bundle Core As Potential Targets for HIV-1 Fusion Inhibitors

Novel Recombinant Engineered Gp41 N-terminal Heptad Repeat Trimers and Their Potential As Anti-Hiv-1 Therapeutics or Microbicides.

A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity.

Site-specific Isopeptide Bridge Tethering of Chimeric gp41 N-terminal Heptad Repeat Helical Trimers for the Treatment of HIV-1 Infection